1. Current concepts in the development of therapeutics against human and animal coronavirus diseases by targeting NP
- Author
-
Wei-Li Hsu, Yeu Yang Tseng, Abigail Lien, and Guan Ru Liao
- Subjects
PRCV, porcine respiratory coronavirus ,viruses ,CoV, coronavirus ,medicine.disease_cause ,Biochemistry ,ECoV, equine coronavirus ,N protein ,0302 clinical medicine ,Structural Biology ,Virtual screen ,Pandemic ,FIPV, feline infectious peritonitis virus ,RNP, ribonucleoproteins ,Coronavirus ,COVID-19, coronavirus disease 2019 ,0303 health sciences ,BCoV, bovine coronavirus ,virus diseases ,MERS-CoV, Middle East respiratory syndrome coronavirus ,PEDV, Porcine epidemic diarrhea virus ,Computer Science Applications ,HIV, human immunodeficiency virus ,030220 oncology & carcinogenesis ,HCoVs, human coronaviruses ,Severe acute respiratory syndrome coronavirus ,nsp3, the nonstructural protein 3 ,Biotechnology ,FECV, feline enteric coronavirus ,Coronavirus disease 2019 (COVID-19) ,TGEV, transmissible gastroenteritis virus ,Middle East respiratory syndrome coronavirus ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,SARS-CoV, severe acute respiratory syndrome coronavirus ,IBV, infectious bronchitis virus ,Biophysics ,Article ,AMP, UMP, GMP and CMP, ribonucleoside 5′-monophosphates ,03 medical and health sciences ,E, envelope protein ,medicine ,Genetics ,NTD, N-terminus RNA-binding domain ,IFN, interferon ,SP, spike protein ,MHV, mouse hepatitis virus ,shRNAs, short hairpin RNAs ,030304 developmental biology ,SeCoV, swine enteric coronavirus ,business.industry ,RBD, RNA-binding domain ,SARS-CoV-2 ,Inhibitors ,Viral nucleocapsid ,CCoV, canine coronavirus ,COVID-19 ,PDCoV, porcine deltacoronavirus ,Virology ,MP, membrane protein ,TCoV, turkey coronavirus ,siRNA, small interfering RNA ,CTD, C-terminus dimerization domain ,Antagonists ,business ,TP248.13-248.65 - Abstract
The coronavirus (CoV) infects a broad range of hosts including humans as well as a variety of animals. It has gained overwhelming concerns since the emergence of deadly human coronaviruses (HCoVs), severe acute respiratory syndrome coronavirus (SARS-CoV) in 2003, followed by Middle East respiratory syndrome coronavirus (MERS-CoV) in 2015. Very recently, special attention has been paid to the novel coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 due to its high mobility and mortality. As the COVID-19 pandemic continues, despite vast research efforts, the effective pharmaceutical interventions are still not available for clinical uses. Both expanded knowledge on structure insights and the essential function of viral nucleocapsid (N) protein are key basis for the development of novel, and potentially, a broad-spectrum inhibitor against coronavirus diseases. This review aimed to delineate the current research from the perspective of biochemical and structural study in cell-based assays as well as virtual screen approaches to identify N protein antagonists targeting not only HCoVs but also animal CoVs.
- Published
- 2021